This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
November 20, 2012 /PRNewswire/ --
NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. for the development and commercialisation in
China of NeuroVive's most clinically advanced products CicloMulsion® and NeuroSTAT®.
Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in
China and the market leader in the fast-growing Chinese cardio-cerebral vascular (CCV) drugs market. The agreement was entered into by Sihuan Pharmaceutical through its wholly-owned subsidiary Sun Moral International (HK) Ltd. and by NeuroVive through its subsidiary NeuroVive Pharmaceutical Asia Ltd.
CicloMulsion® and NeuroSTAT® are in clinical development by NeuroVive for the treatment of heart reperfusion injury after stenting and traumatic brain injury respectively. These are indications of huge medical need for which there are currently no approved pharmaceutical treatment options.
Both products act to prevent the death of mitochondria in damaged cells and the cascade of intracellular biochemical events that lead to secondary tissue damage following a traumatic injury. By protecting a cell's mitochondria NeuroVive's products ensure that energy production is preserved and a damaged cell's normal regenerative mechanisms can act to repair and maintain the cell. CicloMulsion® and NeuroSTAT® contain cyclosporine which, by inhibiting cyclophilin D, prevents the disruption of the membrane of the mitochondria.
Sihuan is a leading Chinese pharmaceutical company with the largest cardio-cerebral vascular drug franchise in
China. It has a proven track record in R&D, manufacturing, sales and marketing of cardio-cerebral vascular drugs. Its nationwide distribution network covers over 10,000 hospitals through over 3,000 distributors making it the ideal partner to bring NeuroVive's drugs to market in
Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: "Our agreement with Sihuan is a transformational event for NeuroVive and provides strong validation of the huge potential of mitochondrial medicine and specifically the work we have done to develop the cyclophilin inhibitors CicloMulsion® and NeuroSTAT®. Sihuan is one of the leading pharmaceutical companies in
China and through this agreement will add significant resources, product development and marketing expertise that will greatly accelerate the development and commercialisation of our products in
China. I look forward to a long and productive partnership with Sihuan that I am confident will lead to the launch of NeuroVive's products for the treatment of acute cardiovascular and neurological conditions in the Chinese market estimated to be worth more than
2 billion RMB annually at peak sales."
Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said: "This is a breakthrough for our business development as it is the first time Sihuan Pharmaceutical is collaborating with a renowned international pharmaceutical company. The collaboration will bring together Sihuan Pharmaceutical's competitive advantages in product development, marketing promotion and distribution network and NeuroVive's advanced drug development technology. This will enrich our product portfolio, raise the level of our product resources and widen our revenue stream. We believe that CicloMulsion® and NeuroSTAT® will become new drivers of our sales, sustain our growth in the long run, and consolidate Sihuan Pharmaceutical's leadership in the CCV drug market. "
Scope of the agreement